Stated in a supplied disclosure. Management reported: “Pipeline development continues Development continues across the Company’s portfolio, including VXM01, Vaximm’s oral T-cell immunotherapy, for which Vaximm is currently preparing a publication of its new data analysis on the completed Phase 2a trial in glioblastoma; Darnatein’s regenerative protein programs, which continue to be the subject of licensing discussions with a potential licensee; and Woori IO’s noninvasive glucose monitoring technology, with numerous parties from around the globe having expressed an interest in potential partnerships.”

Stated in a supplied disclosure. Management reported: “Shareholder Loyalty CVR Program Reflecting its commitment to long-term shareholders, the Company intends to seek to continue its Shareholder Loyalty CVR Program for enrolled holders, including by amending the CVR Agreement so that price thresholds are measured on the principal market on which its common stock is then listed or quoted.” ““Our priority now is making enrollment as clear and straightforward as possible, so that every eligible shareholder is positioned to reap the full benefit of this innovative program should its price milestones be reached,” said Tim Smith, Head of Investor Relations at OSR Health.”